Tagged as: PTAB

Update on IPR Estoppel

Law360 has published an article by contributing editors here at Big Molecule Watch.  The article, titled “IPR Estoppel Takes Shape,” looks at recent cases that discuss the scope of estoppel stemming from inter partes review proceedings.  Click here for a link to the article.

Read More

Big Molecule Team at 2016 BIO IPCC Fall Conference

If you plan to attend next week’s 2016 BIO Intellectual Property Counsels Committee Fall Conference, please keep an eye out for members of the Big Molecule Watch team.  Big Molecule Watch editors Nick Mitrokostas and Cynthia Hardman will moderate the conversation during the day-two luncheon fireside chat, “Standing on the…

Read More

PTO Publishes New PTAB Rules

On April 1, the U.S. Patent & Trademark Office published new rules for AIA proceedings before the Patent Trial & Appeal Board, including inter partes reviews (IPRs).  IPRs are becoming an important tool for biosimilar manufacturers to challenge patents on biologic drugs (for example, see here, here, and here). Some of the most…

Read More